Develop an Alzheimer’s disease modifier, Memrin™. While our research targets several neurodegenerative diseases, we have selected Alzheimer’s because of the immense burden of the disease on patients and families. A French Professor of neurology said about the disease: "It makes two people sick, the patient himself and the caregiver". Our goal is to go beyond the profoundly inadequate symptom relief therapies on the market and alter early the disease through the molecular target called Tau protein. This will slow down the disease, restore smiles and give valuable quality time to patients and caregivers. Memrin™ will be advanced all the way toward human proof-of-concept by our management team using world-class research laboratories, and support from Key Opinion Leaders and our Scientific Advisory Board.